source
- Novo reports 25% average weight loss in women using CagriSema, with greatest loss in premenopausal patientsNovo's next-generation GLP-1 drug CagriSema showed substantial weight loss in women enrolled in the Phase 3 REDEFINE 1 trial. Women in the study lost about 25% of their body weight after 68 weeks,…
- Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testingHologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain. Reveal Genomics develops advanced genomic diagnostic tests, notably the HE…